Bod Australia Ltd (BOD) AI Stock Analysis

• Market Cap: AU$4.26M
• Dividend Yield: N/A
• Average Volume (3M): 0.00
• Price to Earnings (P/E): ―
• Beta (1Y): -1.52
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 177,338,490
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 0
• PEG Ratio: N/A
• Price to Book (P/B): -0.80
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -15.12
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 39 Underperform
• Price Target: ―

Bod Australia Ltd faces significant financial and operational challenges with declining revenues, persistent losses, and negative equity. Technical analysis indicates overbought conditions without clear upward momentum, while valuation metrics are unfavorable due to a negative P/E ratio. These factors suggest a high-risk profile, resulting in a low overall stock score.

Bod Australia Ltd Business Overview & Revenue Model

Company Description

Bod Australia Ltd (BOD) is an innovative health and wellness company specializing in the development, manufacture, and distribution of premium, evidence-based natural products. The company operates primarily within the nutraceutical and medicinal cannabis sectors, offering a range of products that include healthcare supplements, skincare solutions, and medicinal cannabis products. BOD focuses on leveraging scientific research to deliver high-quality products aimed at improving health and well-being.

How the Company Makes Money

Bod Australia Ltd generates revenue through the sale of its diverse product offerings across different channels, including direct-to-consumer sales, partnerships with pharmacies, and international distribution agreements. Key revenue streams include the sale of nutraceutical products, skincare items, and medicinal cannabis products. The company has established significant partnerships with pharmaceutical companies and retail chains, enhancing its distribution capabilities and market reach. Additionally, BOD capitalizes on its research and development initiatives to create innovative products that meet regulatory standards and consumer demands, thereby driving sales and sustaining growth.

Bod Australia Ltd Financial Statement Overview

Summary

Bod Australia Ltd is facing significant financial challenges with declining revenues, persistent losses, and negative profit margins. The balance sheet shows financial distress with negative equity, increasing liabilities, and declining assets. Cash flow issues are evident with negative operating and free cash flows, highlighting a high reliance on external financing.

Income Statement

Bod Australia Ltd shows a declining revenue trend with a significant drop in revenue from 2021 to 2024. Gross profit margins are negative, indicating that the cost of goods sold exceeds sales revenue. The net profit margin is also negative, reflecting consistent losses over the years. The company struggles with EBIT and EBITDA margins staying firmly in the red, underscoring operational inefficiencies and persistent losses.

Balance Sheet

The company's balance sheet reveals a negative stockholders' equity in the recent year, indicating potential financial distress. The debt-to-equity ratio cannot be calculated meaningfully due to negative equity. Total liabilities have increased, while assets have declined, further stressing financial instability. Return on equity is negative due to continuous net losses.

Cash Flow

Bod Australia Ltd's cash flow statement shows negative operating cash flows, reflecting challenges in generating cash from operations. Free cash flow remains negative, indicating high capital expenditures relative to cash generated. Despite these concerns, financing cash flows have provided some relief, though reliance on external funding is a potential risk.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	875.56K	1.72M	3.42M	6.58M	5.01M
Gross Profit	265.90K	-3.08M	498.15K	2.66M	1.14M
EBITDA	-8.03M	-7.98M	-5.48M	-3.95M	-4.00M
Net Income	-6.41M	-7.95M	-5.41M	-4.23M	-4.82M
Balance Sheet
Total Assets	2.31M	3.50M	5.31M	10.35M	8.91M
Cash, Cash Equivalents and Short-Term Investments	434.40K	2.03M	3.67M	8.05M	6.39M
Total Debt	1.83M	963.13K	0.00	0.00	0.00
Total Liabilities	7.63M	4.21M	1.85M	1.69M	4.11M
Stockholders Equity	-5.32M	-703.36K	3.47M	8.66M	4.81M
Cash Flow
Free Cash Flow	-2.87M	-5.83M	-4.38M	-5.86M	-3.68M
Operating Cash Flow	-913.98K	-5.68M	-4.18M	-5.83M	-3.22M
Investing Cash Flow	-1.94M	-289.61K	-207.44K	-26.87K	-463.58K
Financing Cash Flow	764.83K	4.14M	0.00	7.50M	7.23M

Bod Australia Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Neutral
• RSI: Negative
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BOD, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Neutral momentum. The RSI at 100.00 is Negative, neither overbought nor oversold. The STOCH value of -133.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:BOD.

Bod Australia Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	¥355.44B	11.35	-2.99%	2.49%	11.76%	-10.21%
EXL	52 Neutral	$4.60M	―	-21.29%	―	80.87%	82.44%
CAN	46 Neutral	AU$9.77M	―	-164.01%	―	-18.80%	-46.65%
EOF	44 Neutral	AU$7.29M	―	-55.38%	―	-3.82%	79.24%
BOD	39 Underperform	AU$4.26M	―		―	―	―

Bod Australia Ltd Corporate Events

Bod Science Limited Reports Revenue Growth Amid Financial Restructuring

Bod Science Limited, currently under a Deed of Company Arrangement, reported a significant increase in revenue from ordinary activities, up by 38% to $600,659 for the half-year ending December 31, 2024. The company also reported a substantial reduction in net loss, down 99.7% to $16,434, compared to the previous period. Despite these improvements, the company continues to face financial challenges with net tangible liabilities per share slightly increasing to (3.07) cents. Additionally, the dissolution of its UK subsidiary, Aqua Phase Ltd, was noted during this period.

Bod Science Reports Financial Gains Amidst Strategic Restructuring

Bod Science Limited has provided an update for the quarter ending June 30, 2025, highlighting a net cash inflow of $858k from operating activities, driven by an R&D tax incentive and contributions from Biortica. The company is under a Deed of Company Arrangement with Biortica, which involves a Share Purchase Agreement to acquire Biortica’s shares. The DOCA period has been extended to August 7, 2025, due to delays in meeting ASX requirements, with an extraordinary general meeting expected by September 30, 2025. This development is crucial for Bod’s operational continuity and strategic positioning in the cannabis drug development industry.

Bod Science Limited Reports Quarterly Cash Flow

Bod Science Limited reported a net cash inflow from operating activities of $858,000 for the current quarter, supported by government grants and tax incentives totaling $678,000. The company experienced a net decrease in cash and cash equivalents of $26,000 over the year to date, highlighting a challenging financial environment with limited cash flow from investing and financing activities.

Bod Science Limited Announces Change in Principal Place of Business

Bod Science Limited has announced a change in its registered office and principal place of business to a new address in Sydney, Australia. This move, approved by the Deed Administrator, reflects the company’s ongoing restructuring efforts under a Deed of Company Arrangement. The change is part of Bod’s strategic initiatives to strengthen its operational framework and potentially improve its market positioning.

Bod Science Limited Announces Change in Company Secretary

Bod Science Limited has announced a change in its company secretary, with Carlie Hodges resigning and Joanne Patterson being appointed as her replacement. This change occurs as the company continues to operate under a Deed of Company Arrangement, reflecting ongoing restructuring efforts. The appointment of a new company secretary may impact the company’s administrative operations and stakeholder relations as it navigates its current financial and strategic challenges.